{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:26:54Z","timestamp":1787286414869,"version":"build-2736575974"},"reference-count":149,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marie Sk\u0142odowska-Curie Action OncoProTools","award":["101073231"],"award-info":[{"award-number":["101073231"]}]},{"name":"Helmholtz Initiative and Networking Fund","award":["InterLabs-0031"],"award-info":[{"award-number":["InterLabs-0031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of hematologic malignancies but has demonstrated limited efficacy in solid tumors, mainly due to the complex and immunosuppressive tumor microenvironment (TME). Among the strategies to overcome this challenge, targeting the tumor stroma rather than the tumor cells themselves has gained increasing interest. In this context, fibroblast activation protein alpha (FAP), a cell surface protease overexpressed by cancer-associated fibroblasts, represents a promising target. With the aim of remodeling the TME, enhancing immune infiltration, and suppressing tumor growth, numerous FAP-directed CAR T-cell therapies have been developed in the last decade, leading to the clinical translation of two candidates. To improve the flexibility and safety profile of CAR T-cell therapies, several groups have designed more controllable and modular approaches, including adapter CAR T-cell systems, which enable on-demand activation of effector cells through the administration of an adapter molecule. In parallel, the development of FAP-targeted radiotracers, particularly FAP inhibitors (FAPIs), has enabled high-contrast imaging of solid tumors and introduced attractive opportunities for radioligand therapy. The convergence of these advances has given rise to immunotheranostic strategies that integrate CAR T-cell immunotherapy and radioligand delivery within a unified framework. This review traces the evolution of FAP-directed CAR T-cell strategies, from conventional designs to adapter-based and theranostic platforms, and examines how modular adapters bring immunotherapy and radioligand delivery together within a single immunotheranostic framework, across preclinical and clinical settings.<\/jats:p>","DOI":"10.3390\/ijms27167425","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:07:34Z","timestamp":1787148454000},"page":"7425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolution of FAP-Targeted CAR T-Cell Therapy in Solid Tumors: From Immunotherapy to Immunotheranostic Applications"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8164-4306","authenticated-orcid":false,"given":"Hugo","family":"Boutier","sequence":"first","affiliation":[{"name":"Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT\/UCC Dresden, 01307 Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany"},{"name":"National Center for Tumor Diseases (NCT), NCT\/UCC Dresden, 01307 Dresden, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2024). Global Cancer Burden Growing, Amidst Mounting Need for Services."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14216\/kjco.24009","article-title":"The evolution of cancer immunotherapy: A comprehensive review of its history and current perspectives","volume":"20","author":"Ahuja","year":"2024","journal-title":"Korean J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alsaieedi, A.A., and Zaher, K.A. (2025). Tracing the development of CAR-T cell design: From concept to next-generation platforms. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1615212"},{"key":"ref_6","unstructured":"FDA (2026, February 10). Approved Cellular and Gene Therapy Products. FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-025-01760-9","article-title":"Emerging advances in CAR-T therapy for solid tumors: Latest clinical trial updates from 2025 ASCO annual meeting","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Arndt, C., Fasslrinner, F., Loureiro, L.R., Koristka, S., Feldmann, A., and Bachmann, M. (2020). Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12051302"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Joechner, A.H., Mach, M., and Li, Z. (2025). The Current Landscape of Modular CAR T Cells. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262411898"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lee, H.H., and Al-Ogaili, Z. (2025). Fibroblast activation protein and the tumour microenvironment: Challenges and therapeutic opportunities. Oncol. Rev., 19.","DOI":"10.3389\/or.2025.1617487"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imr.12978","article-title":"Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer","volume":"302","author":"Mhaidly","year":"2021","journal-title":"Immunol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1111\/cas.16285","article-title":"Fibroblast activation protein constitutes a novel target of chimeric antigen receptor T-cell therapy in solid tumors","volume":"115","author":"Meng","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., and Zhang, R. (2021). Fibroblast Activation Protein-\u03b1 as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.648187"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Old","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","article-title":"Targeting fibroblast activation protein (FAP): Advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy","volume":"13","author":"Shahvali","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chandekar, K.R., Prashanth, A., Vinjamuri, S., and Kumar, R. (2023). FAPI PET\/CT Imaging\u2014An Updated Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13122018"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41181-025-00356-5","article-title":"Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: A review of current progress","volume":"10","author":"Homedan","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Imlimthan, S., Moon, E.S., Rathke, H., Afshar-Oromieh, A., R\u00f6sch, F., Rominger, A., and Gourni, E. (2021). New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101023"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118737","DOI":"10.1016\/j.ejmech.2026.118737","article-title":"Advancing fibroblast activation protein inhibitors for targeted radioligand therapy: Strategies and innovations to increase tumor residence time","volume":"309","author":"Mattiussi","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2598908","DOI":"10.1080\/2162402X.2025.2598908","article-title":"Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells","volume":"14","author":"Boutier","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s13046-023-02912-w","article-title":"Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment","volume":"42","author":"Loureiro","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2101852118","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Tiruneh","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CNQ.0000000000000302","article-title":"CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies","volume":"43","author":"Rivera","year":"2020","journal-title":"Crit. Care Nurs. Q."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_37","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Soto, K.E.G., Loureiro, L.R., Bartsch, T., Arndt, C., Kegler, A., Mitwasi, N., Drewitz, L., Hoffmann, L., Saleh, H.A., and Crespo, E. (2023). Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1302354"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1659095","DOI":"10.1080\/2162402X.2019.1659095","article-title":"A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR","volume":"8","author":"Arndt","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-\u03b1 targeting: First in-human results","volume":"17","author":"Themelis","year":"2011","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2019-123810","article-title":"A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma","volume":"134","author":"Munoz","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"241.e1","DOI":"10.1016\/j.jtct.2023.10.014","article-title":"Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma","volume":"30","author":"Munoz","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1182\/blood-2021-151727","article-title":"First in Human Study of an on\/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)","volume":"138","author":"Nikolaenko","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S638","DOI":"10.1016\/j.annonc.2023.09.2193","article-title":"1054P A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors","volume":"34","author":"Qin","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2023-177867","article-title":"Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"142","author":"Wermke","year":"2023","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.abb.2006.11.006","article-title":"Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV","volume":"457","author":"Christiansen","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood-2005-08-3452","article-title":"Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein","volume":"107","author":"Lee","year":"2006","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Coppage, A.L., Heard, K.R., DiMare, M.T., Liu, Y., Wu, W., Lai, J.H., and Bachovchin, W.W. (2016). Human FGF-21 Is a Substrate of Fibroblast Activation Protein. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151269"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1074\/jbc.M115.710582","article-title":"Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21","volume":"291","author":"Dunshee","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1074\/mcp.RA118.001046","article-title":"Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cell. Proteom."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0925-4439(97)00032-X","article-title":"Molecular cloning of seprase: A serine integral membrane protease from human melanoma","volume":"1361","author":"Goldstein","year":"1997","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"19441","DOI":"10.1074\/jbc.C500092200","article-title":"Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein \u03b1 *","volume":"280","author":"Aertgeerts","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/bi900257m","article-title":"Using Substrate Specificity of Antiplasmin-Cleaving Enzyme for Fibroblast Activation Protein Inhibitor Design","volume":"48","author":"Lee","year":"2009","journal-title":"Biochemistry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07241.x","article-title":"Fibroblast activation protein \u03b1 identifies mesenchymal stromal cells from human bone marrow","volume":"142","author":"Bae","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00418-014-1292-0","article-title":"Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-IV in the adult human Langerhans islets","volume":"143","author":"Busek","year":"2015","journal-title":"Histochem. Cell Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1007\/s00259-025-07141-1","article-title":"Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study","volume":"52","author":"Bilinska","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"706745","DOI":"10.1155\/2012\/706745","article-title":"Plasma Seprase and DPP4 Levels as Markers of Disease and Prognosis in Cancer","volume":"32","author":"Javidroozi","year":"2012","journal-title":"Dis. Markers"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"132044","DOI":"10.1016\/j.ijcard.2024.132044","article-title":"Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation","volume":"406","author":"Tillmanns","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"npj Imaging"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Liu, F., Qi, L., Liu, B., Liu, J., Zhang, H., Che, D., Cao, J., Shen, J., Geng, J., and Bi, Y. (2015). Fibroblast activation protein overexpression and clinical implications in solid tumors: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116683"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: Back to the basics","volume":"37","author":"Blomberg","year":"2018","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13643-025-02929-6","article-title":"Predicting fibroblast activation protein overexpression in the overall survival rate of cancer patients: A systematic review and meta-analysis","volume":"14","author":"Janani","year":"2025","journal-title":"Syst. Rev."},{"key":"ref_66","first-page":"275","article-title":"Fibroblast activation protein-\u03b1 promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways","volume":"41","author":"Jia","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1155","DOI":"10.1038\/cddis.2014.122","article-title":"Downregulation of FAP suppresses cell proliferation and metastasis through PTEN\/PI3K\/AKT and Ras-ERK signaling in oral squamous cell carcinoma","volume":"5","author":"Wang","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3892\/ijo.2012.1475","article-title":"Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells","volume":"41","author":"Lai","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1172\/JCI38988","article-title":"Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice","volume":"119","author":"Santos","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Biffi","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: From basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ccell.2025.03.004","article-title":"Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics","volume":"43","author":"Liu","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Diminished Survival","volume":"25","author":"Carstens","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/1078-0432.CCR-25-2907","article-title":"Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer","volume":"32","author":"Armstrong","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-25-0663","article-title":"Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic Tumors","volume":"14","author":"Bajbouj","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/2326-6066.CIR-25-0349","article-title":"The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity","volume":"14","author":"Chantzoura","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Das, S., Valton, J., Duchateau, P., and Poirot, L. (2023). Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1172681"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1016\/j.ymthe.2024.08.018","article-title":"TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity","volume":"32","author":"Dharani","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"405","DOI":"10.24976\/Discov.Med.202335176.41","article-title":"Development of FAP-Targeted Chimeric Antigen Receptor NK-92 Cells for Non-Small Cell Lung Cancer","volume":"35","author":"Fang","year":"2023","journal-title":"Discov. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"29","DOI":"10.25259\/Cytojournal_245_2024","article-title":"Enhanced efficacy of dual chimeric antigen receptor-T cells targeting programmed death-ligand 1 and cancer-associated fibroblasts in colorectal cancer in vitro","volume":"22","author":"Gao","year":"2025","journal-title":"CytoJournal"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1158\/1078-0432.CCR-17-1788","article-title":"Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice","volume":"24","author":"Gulati","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e54275","DOI":"10.15252\/embr.202154275","article-title":"Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors","volume":"23","author":"Jiang","year":"2022","journal-title":"EMBO Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1158\/1078-0432.CCR-22-1379","article-title":"Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Li, F., Zhao, S., Wei, C., Hu, Y., Xu, T., Xin, X., Zhu, T., Shang, L., Ke, S., and Zhou, J. (2022). Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.958082"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12967-023-04080-z","article-title":"FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"116604","DOI":"10.1016\/j.bcp.2024.116604","article-title":"Targeting fibroblast activation protein with chimeric antigen receptor macrophages","volume":"230","author":"Mao","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41598-025-31128-5","article-title":"Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models","volume":"16","author":"Meng","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Niu, W., Wang, B., Zhang, Y., Wang, C., Cao, J., Li, J., He, Y., and Lei, P. (2024). Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1433679"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41419-025-08405-2","article-title":"A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a TSCM subset in the TME","volume":"17","author":"Pang","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2556714","DOI":"10.1080\/2162402X.2025.2556714","article-title":"Anti-FAP CAR-NK cells as a novel targeted therapy against cervical cancer and cancer-associated fibroblasts","volume":"14","author":"Polten","year":"2025","journal-title":"Oncoimmunology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1111\/bph.16505","article-title":"Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer","volume":"181","author":"Sun","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/blood.2021012811","article-title":"Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma","volume":"139","author":"Sakemura","year":"2022","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","article-title":"Generation of Potent T-cell Immunotherapy for Cancer using DAP12-based, Multichain, Chimeric Immunoreceptors","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"113888","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T Cells Secreting Anti-FAP\/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1519","DOI":"10.1002\/cti2.1519","article-title":"Endogenous bystander killing mechanisms enhance the activity of novel FAP-specific CAR-T cells against glioblastoma","volume":"13","author":"Yu","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"200817","DOI":"10.1016\/j.omton.2024.200817","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.iotech.2020.09.001","article-title":"Function and evolution of the prototypic CD28\u03b6 and 4-1BB\u03b6 chimeric antigen receptors","volume":"8","author":"Feucht","year":"2020","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Petrausch, U., Schuberth, P.C., Hagedorn, C., Soltermann, A., Tomaszek, S., Stahel, R., Weder, W., and Renner, C. (2012). Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-615"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"v501","DOI":"10.1093\/annonc\/mdz253.052","article-title":"1226P\u2014A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","volume":"30","author":"Curioni","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"P120","DOI":"10.1186\/2051-1426-3-S2-P120","article-title":"FAP-specific re-directed T cells first in-man study in malignant pleural mesothelioma: Experience of the first patient treated","volume":"3","author":"Pircher","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2967\/jnumed.107.047787","article-title":"Recommendations on the Use of 18F-FDG PET in Oncology","volume":"49","author":"Fletcher","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/JCIS_209_2025","article-title":"Fibroblast activation protein-targeted radiopharmaceuticals: Recent trends in cancer diagnosis","volume":"16","author":"Huang","year":"2026","journal-title":"J. Clin. Imaging Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.117.199877","article-title":"Dual-Targeted Molecular Imaging of Cancer","volume":"59","author":"Ehlerding","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e220157","DOI":"10.1148\/rycan.220157","article-title":"A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2125.2001.01335.x","article-title":"Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients","volume":"51","author":"Tanswell","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_120","first-page":"1639","article-title":"A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1158\/1078-0432.CCR-12-0644","article-title":"Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies","volume":"18","author":"Fischer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Pandya, D.N., Sinha, A., Yuan, H., Mutkus, L., Stumpf, K., Marini, F.C., and Wadas, T.J. (2020). Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography. Molecules, 25.","DOI":"10.3390\/molecules25163672"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-20-1358","article-title":"Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography","volume":"26","author":"Hintz","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/cbmi.3c00067","article-title":"225Ac-Labeled Antibody for Fibroblast Activation Protein-Targeted Alpha Therapy","volume":"1","author":"Song","year":"2023","journal-title":"Chem. Biomed. Imaging"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1007\/s00259-023-06300-6","article-title":"An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy","volume":"50","author":"Xu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: Background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Boussihmad","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Wu, X., Wang, Y., Li, Y., and Hu, W. (2025). Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors. Front. Nucl. Med., 5.","DOI":"10.3389\/fnume.2025.1737443"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","article-title":"Fibroblast Activation Protein Inhibitor\u2013Based Radionuclide Therapies: Current Status and Future Directions","volume":"64","author":"Ora","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_134","first-page":"476","article-title":"Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: A step to improve tumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Martin, M., Ballal, S., Yadav, M.P., Bal, C., Van Rymenant, Y., De Loose, J., Verhulst, E., De Meester, I., Van Der Veken, P., and Roesch, F. (2023). Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics. Cancers, 15.","DOI":"10.3390\/cancers15061889"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_137","first-page":"242105","article-title":"Development of PET Imaging for Fibroblast Activation Protein Using Novel FAPI-Multimeric HMFB-n Derivatives","volume":"65","author":"Yang","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1021\/acs.molpharmaceut.4c00327","article-title":"Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation","volume":"21","author":"Feng","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s44303-024-00028-0","article-title":"Increased imaging ligand hydrophilicity and improved pharmacokinetic properties provides enhanced in vivo targeting of fibroblast activation protein","volume":"2","author":"Narain","year":"2024","journal-title":"npj Imaging"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin Binder\u2013Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"21739","DOI":"10.1021\/acs.jmedchem.5c02102","article-title":"Structure\u2013Property Investigation of New \u201cKetoFAPI\u201d Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential","volume":"68","author":"Brzeminski","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): Next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Moon, E.S., Van Rymenant, Y., Battan, S., De Loose, J., Bracke, A., Van der Veken, P., De Meester, I., and R\u00f6sch, F. (2021). In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi. Molecules, 26.","DOI":"10.3390\/molecules26123482"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Huang, B., Zheng, S., Sudarshan, K., Mukkamala, R., Srinivasarao, M., Sardesai, T., Yang, X., Chu, H., and Low, P.S. (2025). Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1539265"},{"key":"ref_147","unstructured":"Boutier, H., Mattiussi, S., Loureiro, L.R., Berndt, N., Stammberger, A., Jones-Cifuentes, N., Hoffmann, L., Verhulst, E., Schmitz, M., and De Meester, I. (2026). Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells. Oncoimmunology."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Boutier, H., Loureiro, L.R., Hoffmann, L., Arndt, C., Bartsch, T., Feldmann, A., and Bachmann, M.P. (2024). UniCAR T-Cell Potency-A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137242"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.biomaterials.2018.06.021","article-title":"Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicines","volume":"179","author":"Edem","year":"2018","journal-title":"Biomaterials"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:21:01Z","timestamp":1787286061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":149,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167425"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167425","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}